Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma.

Folia neuropathologica - 1 Jan 2023

Butt Nadeem, Enani Maryam, Alshanqiti Maryam, Alkhotani Alaa, Alsinani Taghreed, Karami Mohammed Matoog, Fadul Motaz M, Almansouri Majid, Hassan Amber, Baeesa Saleh, Bamaga Ahmed K, Alkhayyat Shadi, Faizo Eyad, Kurdi Maher

Abstract excerpt

INTRODUCTION: CD8 + T-cells and MHC-I have been detected in brain gliomas with a significant outcome. The effect of chemotherapies on the crosstalk interaction between CD8 + T-cells and MHC-I has never been explored. MATERIAL AND METHODS: The protein expression profiling of CD8 cytotoxic T-cells and the gene expression assay of MHC-I in 35 patients diagnosed with WHO grade 4 astrocytoma were performed. The impact...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to Neoplasm Recurrence, Local

Share to Temozolomide

Share to Tumor Microenvironment

Share to World Health Organization

Source

Identifiers

PMID: 37818692
DOI: 10.5114/fn.2023.131014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma.PMID 37818692Read ↗

Major Histocompatibility Class-I (MHC-I) downregulation in glioblastoma is a poor prognostic factor but not a predictive indicator for treatment failure.Semantic proximity Read ↗

The synergistic effect of IDH mutation and NDRG-2 dysregulation in the progression of WHO-grade 4 astrocytomas.Semantic proximity Read ↗

Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution.Semantic proximity Read ↗

Molecular and Clinical Determinants of Response to Immunotherapy in High-Grade GliomaSemantic proximity Read ↗

Long-term survival after local immunotherapy for malignant gliomas: a retrospective study with 20 years follow-up.Semantic proximity Read ↗

Immune profiling of gliomas reveals a connection with Tau function and the tumor vasculature.Semantic proximity Read ↗

Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas.Semantic proximity Read ↗

Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.Semantic proximity Read ↗

Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study.Semantic proximity Read ↗

Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed GlioblastomaSemantic proximity Read ↗

Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.Semantic proximity Read ↗

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.